{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:16:47Z","timestamp":1790302607006,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011199","name":"FP7 Ideas: European Research Council","doi-asserted-by":"publisher","award":["667787"],"award-info":[{"award-number":["667787"]}],"id":[{"id":"10.13039\/100011199","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Activating G\u03b1\n                      <jats:sub>q<\/jats:sub>\n                      signalling mutations are considered an early event in the development of uveal melanoma. Whereas most tumours harbour a mutation in\n                      <jats:italic>GNAQ<\/jats:italic>\n                      or\n                      <jats:italic>GNA11<\/jats:italic>\n                      ,\n                      <jats:italic>CYSLTR2<\/jats:italic>\n                      (encoding G-protein coupled receptor CysLT\n                      <jats:sub>2<\/jats:sub>\n                      R) forms a rare alternative. The role of wild-type CysLT\n                      <jats:sub>2<\/jats:sub>\n                      R in uveal melanoma remains unknown.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a digital PCR-based molecular analysis of benign choroidal nevi and primary uveal melanomas. Publicly available bulk and single cell sequencing data were mined to further study mutant and wild-type\n                      <jats:italic>CYSLTR2<\/jats:italic>\n                      in primary and metastatic uveal melanoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      1\/16 nevi and 2\/120 melanomas carried the\n                      <jats:italic>CYSLTR2<\/jats:italic>\n                      mutation. The mutation was found in a subpopulation of the nevus, while being clonal in both melanomas. In the melanomas, secondary, subclonal\n                      <jats:italic>CYSLTR2<\/jats:italic>\n                      alterations shifted the allelic balance towards the mutant. The resulting genetic heterogeneity was confirmed in distinct areas of both tumours. At the RNA level, further silencing of wild-type and preferential expression of mutant\n                      <jats:italic>CYSLTR2<\/jats:italic>\n                      was identified, which was also observed in two\n                      <jats:italic>CYSLTR2<\/jats:italic>\n                      mutant primary melanomas and one metastatic lesion from other cohorts. In\n                      <jats:italic>CYSLTR2<\/jats:italic>\n                      wild-type melanomas, high expression of\n                      <jats:italic>CYSLTR2<\/jats:italic>\n                      correlated to tumour inflammation, but expression originated from melanoma cells specifically.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our findings suggest that\n                      <jats:italic>CYSLTR2<\/jats:italic>\n                      is involved in both early and late development of uveal melanoma. Whereas the\n                      <jats:italic>CYSLTR2<\/jats:italic>\n                      p.L129Q mutation is likely to be the initiating oncogenic event, various mechanisms further increase the mutant allele abundance during tumour progression. This makes mutant CysLT\n                      <jats:sub>2<\/jats:sub>\n                      R an attractive therapeutic target in uveal melanoma.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-07865-x","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T10:51:38Z","timestamp":1613559098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Rogier J.","family":"Nell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino V.","family":"Menger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorius P. M.","family":"Luyten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Verdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele C.","family":"Madigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine J.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"12","key":"7865_CR1","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","volume":"114","author":"G Virgili","year":"2007","unstructured":"Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114(12):2309\u201315.","journal-title":"Ophthalmology"},{"issue":"1","key":"7865_CR2","first-page":"143","volume":"18","author":"AD Singh","year":"2005","unstructured":"Singh AD, Borden EC. Metastatic Uveal Melanoma. Ophthalmol Clin. 2005;18(1):143\u201350.","journal-title":"Ophthalmol Clin"},{"issue":"2","key":"7865_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/eye.2012.255","volume":"27","author":"SE Coupland","year":"2013","unstructured":"Coupland SE, Lake SL, Zeschnigk M, Damato BE. Molecular pathology of uveal melanoma. Eye (Lond). 2013;27(2):230\u201342.","journal-title":"Eye (Lond)"},{"issue":"7229","key":"7865_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nature07586","volume":"457","author":"CD Van Raamsdonk","year":"2009","unstructured":"Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599\u2013602.","journal-title":"Nature"},{"issue":"23","key":"7865_CR5","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","volume":"363","author":"CD Van Raamsdonk","year":"2010","unstructured":"Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191\u20139.","journal-title":"N Engl J Med"},{"issue":"35","key":"7865_CR6","doi-asserted-by":"publisher","first-page":"37824","DOI":"10.18632\/oncotarget.5637","volume":"6","author":"MJ de Lange","year":"2015","unstructured":"de Lange MJ, van Pelt SI, Versluis M, Jordanova ES, Kroes WG, Ruivenkamp C, et al. Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma. Oncotarget. 2015;6(35):37824\u201335.","journal-title":"Oncotarget"},{"issue":"6","key":"7865_CR7","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/bjc.2017.259","volume":"117","author":"MJC Vader","year":"2017","unstructured":"Vader MJC, Madigan MC, Versluis M, Suleiman HM, Gezgin G, Gruis NA, et al. GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. Br J Cancer. 2017;117(6):884\u20137.","journal-title":"Br J Cancer"},{"issue":"4","key":"7865_CR8","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.18632\/oncotarget.6614","volume":"7","author":"P Johansson","year":"2016","unstructured":"Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 2016;7(4):4624\u201331.","journal-title":"Oncotarget."},{"issue":"6","key":"7865_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ng.3549","volume":"48","author":"AR Moore","year":"2016","unstructured":"Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet. 2016;48(6):675\u201380.","journal-title":"Nat Genet"},{"key":"7865_CR10","doi-asserted-by":"publisher","unstructured":"Ceraudo E, Horioka M, Mattheisen JM, Hitchman TD, Moore AR, Kazmi MA, et al. 2019. https:\/\/doi.org\/10.1101\/663153.","DOI":"10.1101\/663153"},{"issue":"1","key":"7865_CR11","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1038\/s41467-019-13348-2","volume":"10","author":"A Gusach","year":"2019","unstructured":"Gusach A, Luginina A, Marin E, Brouillette RL, Besserer-Offroy E, Longpre JM, et al. Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors. Nat Commun. 2019;10(1):5573.","journal-title":"Nat Commun"},{"issue":"6","key":"7865_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000312669","volume":"85","author":"RK Singh","year":"2010","unstructured":"Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology. 2010;85(6):336\u201349.","journal-title":"Pharmacology."},{"issue":"2","key":"7865_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in Uveal melanoma. Cancer Cell. 2017;32(2):204\u201320 e15.","journal-title":"Cancer Cell"},{"issue":"1","key":"7865_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41467-019-14256-1","volume":"11","author":"MA Durante","year":"2020","unstructured":"Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat Commun. 2020;11(1):496.","journal-title":"Nat Commun"},{"issue":"1","key":"7865_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.yexmp.2012.06.004","volume":"94","author":"R van Eijk","year":"2013","unstructured":"van Eijk R, Stevens L, Morreau H, van Wezel T. Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis. Exp Mol Pathol. 2013;94(1):121\u20135.","journal-title":"Exp Mol Pathol"},{"issue":"3","key":"7865_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116371","volume":"10","author":"M Versluis","year":"2015","unstructured":"Versluis M, de Lange MJ, van Pelt SI, Ruivenkamp CA, Kroes WG, Cao J, et al. Digital PCR validates 8q dosage as prognostic tool in uveal melanoma. PLoS One. 2015;10(3):e0116371.","journal-title":"PLoS One"},{"key":"7865_CR17","first-page":"1","volume":"2019","author":"WH Zoutman","year":"1884","unstructured":"Zoutman WH, Nell RJ, van der Velden PA. Usage of droplet digital PCR (ddPCR) assays for T cell quantification in Cancer. Methods Mol Biol. 1884;2019:1\u201314.","journal-title":"Methods Mol Biol"},{"key":"7865_CR18","volume-title":"Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv:12073907","author":"E Garrison","year":"2012","unstructured":"Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv:12073907; 2012."},{"issue":"16","key":"7865_CR19","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment\/map format and SAMtools. Bioinformatics. 2009;25(16):2078\u20139.","journal-title":"Bioinformatics."},{"issue":"8","key":"7865_CR20","doi-asserted-by":"publisher","first-page":"100139","DOI":"10.1016\/j.xcrm.2020.100139","volume":"1","author":"V Anagnostou","year":"2020","unstructured":"Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW, et al. Integrative tumor and immune cell multi-omic analyses predict response to immune checkpoint blockade in melanoma. Cell Rep Med. 2020;1(8):100139.","journal-title":"Cell Rep Med"},{"issue":"7","key":"7865_CR21","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM III, et al. Comprehensive Integration of Single-Cell Data. Cell. 2019;177(7):1888\u2013902.e21.","journal-title":"Cell"},{"issue":"1","key":"7865_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41698-018-0051-4","volume":"2","author":"MC Wagle","year":"2018","unstructured":"Wagle MC, Kirouac D, Klijn C, Liu B, Mahajan S, Junttila M, et al. A transcriptional MAPK pathway activity score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis Oncol. 2018;2(1):7.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"7865_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1054","volume":"33","author":"PM Pollock","year":"2002","unstructured":"Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2002;33(1):19\u201320.","journal-title":"Nat Genet"},{"issue":"12","key":"7865_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/jnci\/djt119","volume":"105","author":"I Yeh","year":"2013","unstructured":"Yeh I, von Deimling A, Bastian BC. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. J Natl Cancer Inst. 2013;105(12):917\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"7865_CR25","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jid.2020.03.938","volume":"140","author":"E Christodoulou","year":"2020","unstructured":"Christodoulou E, Nell RJ, Verdijk RM, Gruis NA, van der Velden PA, van Doorn R. Loss of wild-type CDKN2A is an early event in the development of melanoma in FAMMM syndrome. J Invest Dermatol. 2020;140(11):2298\u2013301 e3.","journal-title":"J Invest Dermatol"},{"issue":"20","key":"7865_CR26","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","volume":"373","author":"AH Shain","year":"2015","unstructured":"Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373(20):1926\u201336.","journal-title":"N Engl J Med"},{"issue":"7","key":"7865_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","volume":"51","author":"AH Shain","year":"2019","unstructured":"Shain AH, Bagger MM, Yu R, Chang D, Liu S, Vemula S, et al. The genetic evolution of metastatic uveal melanoma. Nat Genet. 2019;51(7):1123\u201330.","journal-title":"Nat Genet"},{"issue":"18","key":"7865_CR28","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1158\/1078-0432.CCR-19-1215","volume":"25","author":"M Rodrigues","year":"2019","unstructured":"Rodrigues M, Mobuchon L, Houy A, Alsafadi S, Baulande S, Mariani O, et al. Evolutionary routes in metastatic Uveal melanomas depend on MBD4 alterations. Clin Cancer Res. 2019;25(18):5513\u201324.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7865_CR29","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1038\/s41467-020-15606-0","volume":"11","author":"J Karlsson","year":"2020","unstructured":"Karlsson J, Nilsson LM, Mitra S, Alsen S, Shelke GV, Sah VR, et al. Molecular profiling of driver events in metastatic uveal melanoma. Nat Commun. 2020;11(1):1894.","journal-title":"Nat Commun"},{"issue":"1","key":"7865_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ccell.2018.06.005","volume":"34","author":"AH Shain","year":"2018","unstructured":"Shain AH, Joseph NM, Yu R, Benhamida J, Liu S, Prow T, et al. Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution. Cancer Cell. 2018;34(1):45\u201355.e4.","journal-title":"Cancer Cell"},{"issue":"7315","key":"7865_CR31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596\u20139.","journal-title":"Nature."},{"issue":"2\u20133","key":"7865_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10555-018-9751-z","volume":"37","author":"K Slater","year":"2018","unstructured":"Slater K, Hoo PS, Buckley AM, Piulats JM, Villanueva A, Portela A, et al. Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. Cancer Metastasis Rev. 2018;37(2\u20133):335\u201345.","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"7865_CR33","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1167\/iovs.11-9280","volume":"53","author":"IH Bronkhorst","year":"2012","unstructured":"Bronkhorst IH, Vu TH, Jordanova ES, Luyten GP, Burg SH, Jager MJ. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci. 2012;53(9):5370\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"7865_CR34","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1158\/1541-7786.MCR-18-0114","volume":"16","author":"MJ de Lange","year":"2018","unstructured":"de Lange MJ, Nell RJ, Lalai RN, Versluis M, Jordanova ES, Luyten GPM, et al. Digital PCR-based T-cell quantification-assisted Deconvolution of the microenvironment reveals that activated macrophages drive tumor inflammation in Uveal melanoma. Mol Cancer Res. 2018;16(12):1902\u201311.","journal-title":"Mol Cancer Res"},{"issue":"10","key":"7865_CR35","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1097\/PAS.0000000000001299","volume":"43","author":"K Goto","year":"2019","unstructured":"Goto K, Pissaloux D, Paindavoine S, Tirode F, de la Fouchardiere A. CYSLTR2-mutant cutaneous melanocytic neoplasms frequently simulate \"pigmented Epithelioid Melanocytoma,\" expanding the morphologic Spectrum of blue tumors: a Clinicopathologic study of 7 cases. Am J Surg Pathol. 2019;43(10):1368\u201376.","journal-title":"Am J Surg Pathol"},{"key":"7865_CR36","doi-asserted-by":"crossref","unstructured":"Slater K, Heeran AB, Garcia-Mulero S, Kalirai H, Sanz-Pamplona R, Rahman A, et al. High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. Cancers (Basel). 2020;12(10):2950.","DOI":"10.3390\/cancers12102950"},{"key":"7865_CR37","doi-asserted-by":"crossref","unstructured":"Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, et al. Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nat Commun. 2018;9(1):884\u20137.","DOI":"10.1038\/s41467-017-02428-w"},{"issue":"1","key":"7865_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5858\/2007-131-91-THDOMI","volume":"131","author":"W Maat","year":"2007","unstructured":"Maat W, Jordanova ES, van Zelderen-Bhola SL, Barthen ER, Wessels HW, Schalij-Delfos NE, et al. The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fine-needle aspiration biopsies. Arch Pathol Lab Med. 2007;131(1):91\u20136.","journal-title":"Arch Pathol Lab Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07865-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-07865-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07865-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T12:08:25Z","timestamp":1613563705000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-07865-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7865"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-07865-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.09.16.20191791","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 choroidal nevi were dissected from 13 formalin-fixed post-mortem human donor eyes, with consent from Lions NSW Eye Bank and approval from the University of Sydney and University of New South Wales Human Research Ethics Committee [\n                      \n                      ]. 120 fresh-frozen tumour samples, obtained from primary uveal melanomas treated by enucleation, were available from the Biobank of the Department of Ophthalmology, LUMC. This study was approved by the LUMC Biobank Committee and Medisch Ethische Toetsingscommissie under no. B14.003\/DH\/sh and B20.026. All patient samples were collected with informed consent, which was obtaind verbally as agreed by the medical ethical committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}